Antifibrotic tendency as complement to inflammatory burnout? Six year IVIG treatment in a case with atherosclerosis and chronic hepatitis C.
Rewald
E
E
rewald@arnet.com.ar
D000368:Aged; D001161:Arteriosclerosis / Q000150:complications / Q000188:drug therapy*; D005355:Fibrosis / Q000517:prevention & control; D005500:Follow-Up Studies; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007249:Inflammation / Q000188:drug therapy; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D011994:Recombinant Proteins; D013997:Time Factors
D016756:Immunoglobulins, Intravenous; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins